Platelet-rich thrombi are resistant to lysis by tissue-type plasminogen activator (t-PA). Although platelet a-granules contain plasminogen activator inhibitor-l (PAI-l), a fastacting inhibitor of t-PA, the contribution of PAL1 to the antifibrinolytic effect of platelets has remained a subject of controversy. We recently reported a patient with a homozygous mutation within the PAL1 gene that results in complete loss of PAL1 expression. Platelets from this individual constitute a unique reagent with which to probe the role of platelet PAL1 in the regulation of fibrinolysis. The effects of PAI-1 -deficient platelets were compared with those of normal platelets in an in vitro clot lysis assay. Although the incorporation of PAI-1-deficient platelets into clots resulted in a moderate inhibition of t-PA-mediated fibrino-T ISSUE-TYPE PLASMINOGEN activator (t-PA) dissolves blood clots by catalyzing the conversion of plasminogen to plasmin, a serine protease that efficiently cleaves fibrin. Under physiologic conditions, fibrinolysis is initiated by the release of t-PA from vascular endothelial cells.' In addition, recombinant t-PA is used therapeutically to induce thrombolysis in a variety of clinical settings, most notably myocardial infarction.' However, the rate with which t-PA induces fibrinolysis in vivo is highly variable, and some thrombi are resistant to lysis, despite the administration of pharmacologic concentrations of t-PA.3 Although several factors determine the thrombolytic efficiency of t-PA, the composition of a thrombus appears to be an important determinant of its sensitivity to lysis. In animal models, platelet-rich thrombi are highly resistant to lysis by t-PA," suggesting that platelets exert a potent negative effect on t-PAmediated clot lysis. In addition, human platelets inhibit clot lysis in ~i t r o .~.~ Because human coronary thrombi are frequently platelet-rich,' the antifibrinolytic capacity of platelets may play an important role in the regulation of coronary thrombolysis." Consistent with this hypothesis, antiplatelet agents enhance the efficacy of thrombolytic therapy in patients with acute myocardial infarction.2
lysis, normal platelets markedly inhibited clot lysis under the same conditions. However, no difference between PAIl-deficient platelets and platelets with normal PAL1 content was observed when streptokinase or a PAL1 -resistant t-PA mutant were used to initiate fibrinolysis. In addition, PAl-l-resistant t-PA was significantly more efficient in lysing clots containing normal platelets than wild-type t-PA. We conclude that platelets inhibit t-PAmediated fibrinolysis by both PAI-1-dependent and PAI-1 -independent mechanisms. These results have important implications for the role of PAI-1 in the resistance of platelet-rich thrombi to lysis in vivo.
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Platelets are a major reservoir of PAI-1, with approximately 90% of circulating PAL 1 contained within platelet a-granules." Hence, it has been proposed that the inhibitory effect of platelets on clot lysis is mediated, at least in part, by PAL 1 . 6 However, platelet PAL 1 exists predominantly in a latent, or inactive form,20-22 suggesting that its effect on fibrinolysis may be limited. Prior studies addressing the role of platelet PAI-1 in fibrinolysis have yielded discordant results. Although anti-PAI-1 monoclonal antibodies enhance t-PA-mediated lysis of platelet-rich clots in vitro: studies by other investigators have suggested that platelets inhibit clot lysis by inducing clot retraction, not by PAL 1 release. I3 If platelet PAL 1 regulates clot lysis, then altered expression ofthis inhibitor within the platelet compartment would be expected to affect the lysis of platelet-rich clots. We recently have identified a patient with complete PAL1 deficiency caused by a homozygous frame-shift mutation within exon 4 of the PAI-1 gene.18 This mutation results in the synthesis of an unstable PAI-I mRNA and a truncated PAI-1 protein that lacks the reactive center of the molecule. Platelets from this individual contain no detectable PAI-1, but are otherwise normal. Hence, they constitute a unique reagent to probe the contribution of PAL 1 to platelet-mediated clot lysis resistance. We have compared the effects of PAI-l-deficient platelets with those of normal platelets in an in vitro clot lysis assay in which fibrinolysis was initiated by wild-type t-PA, streptokinase, or a mutant t-PA that is resistant to inhibition by PAL 1. The results of these studies suggest that platelets inhibit fibrinolysis by both PAI-I -dependent and PAI-1 -independent mechanisms.
MATERIALS AND METHODS

Materials.
Recombinant human t-PA (single chain; specific activity, 580,000 IU/mg) was obtained from Genentech (South San Francisco, CA). A recombinant human single-chain t-PA mutant (Lys-296, Arg-298, Arg 299 + Glu) that activates plasminogen normally, but which is highly resistant to inhibition by PAL1 (inhibition rate constant 5.
S-' for wild-type t-PA), was prepared as previously described. 23 The specific activity of mutant t-PA (determined by comparison to wildtype t-PA in the clot lysis assay described below) was approximately 250,000 IU/mg. Streptokinase (specific activity, approximately 3,000 IU/mg) and human Glu-plasminogen were from American Diagnostica (Greenwich, CT). Fibrinogen (prepared from human plasma by p-alanine precipitati~n~~ and lysine-sepharose chromatograph~*~) was the gift of M. Naski. Prostaglandin E,, apyrase, human thrombin, and fluorescein isothiocyanate were from Sigma (St Louis, MO).
Platelet preparations. Blood samples were collected from an individual with homozygous PAI-1 deficiency, an individual heterozygous for the PAL I null allele (father of the homozygous individual), and from normal controls. The clinical characteristics and molecular genetic analysis of this PAI-l-deficiency pedigree have been reported previously.'8 The individual with homozygous PAI-I deficiency (proband) was a IO-year-old female with a congenital bleeding disorder of moderate severity. Routine indices of hemostatic function were normal. However, she had no detectable PAI-1 antigen or activity in either her plasma or platelets. Plasma levels of a2-antiplasmin and factor XI11 were normal. Her bleeding time was mildly prolonged (12 minutes; normal, <9), but in vitro platelet aggregation studies were normal. The probands father had no history of abnormal bleeding. His plasma levels of PAL 1 activity and antigen were in the low to normal range (activity, 0. All individuals from whom blood was collected for these experiments had not consumed aspirin for at least 7 days before venipuncture. After obtaining informed consent, blood samples were collected by peripheral venipuncture into acid-citratedextrose anticoagulant (0.8% wt/vol citric acid, 2.2% trisodium citrate, 2.4590 dextrose) at a ratio of 6 v01 ofblood to 1 v01 ofanticoagulant.
Washed platelets were prepared by repeated centrifugation as previously describedz6 and then resuspended in Tyrode's buffer (1 37 mmol/L NaCI, 2.68 mmol/L KCl, 2 mmol/L CaC12, 1 mmol/L MgCI2, 0.36 mmol/L NaH2P04, 1 1.9 mmol/L NaHCO,, 5 mmol/ L HEPES, 0.1% glucose, 0.35% bovine serum albumin, pH 7.35).
In vitro clot lysis assay. Clot lysis assays were performed by modification of the method of Smith et al?' in which fluoresceinlabeled fibrinogen is clotted by thrombin and plasminogen activator-mediated fibrinolysis is monitored by the release of fluoresceinlabeled fibrin degradation products into the clot supernatant. The concentrations of t-PA, plasminogen, fibrinogen, and platelets in these assays were similar to those used in the clot lysis assay of Levi et aL6 A mixture of Glu-plasminogen (20.8 &nL), fluoresceinlabeled fibrinogen ( I .04 mg/mL), washed platelets (0 to 2.5 X lo8/ mL), and t-PA or streptokinase in Tyrode's buffer was prepared. Aliquots of this mixture (l25 pL) were clotted in 1.5 mL polypropylene tubes by the addition of 5 pL of thrombin (0.2 mmol/L) and then incubated at 37°C. At timed intervals (with I O minutes after the addition of thrombin defined as t = 0), tubes were centrifuged (16,OOOg for 3 minutes) and 100 pL of the clot supematant was removed and diluted into 1. 4 mL of IO mmol/L Tris-HCI, 140 mmol/L NaC1, pH 7.5. The fluorescence of this dilution was measured (excitation wavelength, 500 nm; emission wavelength, 520 nm) in a fluorometer (SLM Instruments, Urbana, IL) and the percentage of clot lysis was calculated as previously described.*'
RESULTS
Effect ofplatelets on t-PA-mediated clot lysis. To determine the effect of normal platelets on fibrinolysis in this experimental system, fibrin clots were formed in the presence or absence of platelets and the rates of wild-type t-PA-mediated clot lysis were compared. The concentration of t-PA in these experiments was 0.67 U/mL. In the absence of platelets, clot lysis was greater than 90% complete within 120 minutes at 37°C (Fig l) . However, in the presence of normal platelets (2.5 X 108/mL), clot lysis was markedly inhibited, with less than 1% clot lysis occurring by 120 minutes. Essentially identical results ( 5 1% clot lysis by 120 minutes in the presence of platelets) were obtained when this experiment was repeated with platelets obtained from 3 other normal individuals.
The effects on clot lysis of washed platelets obtained from the individual with homozygous PAI-l deficiency were compared with those of platelets from a normal control (Fig  2) . Whereas essentially no lysis occurred by 120 minutes in the control reaction, 42% clot lysis was observed in the presence of platelets from the PAI-1 -deficient individual. This experiment was repeated at a later date with a second sample of freshly prepared platelets, and similar, although less marked, results were obtained ( 17% clot lysis at 120 minutes in the presence of PAL 1 -deficient platelets v 1 % clot lysis in the presence of normal platelets). During the latter experiment, the effects on clot lysis of washed platelets prepared from the proband's father were also studied. These platelets markedly inhibited clot lysis (< 1 % lysis by 120 minutes), producing an effect indistinguishable from that of normal platelets. These results are consistent with the normal levels of platelet PAI-1 activity and antigen previously observed in carriers of this defective PAI-1 allele.18
The effect of platelet concentration on t-PA-mediated clot lysis was also examined. Clot lysis was allowed to occur for 60 minutes in the presence of t-PA (0.67 U/mL) and platelets (0 to 2.4 X 108/mL). For both normal and homozygous PAL 1 -deficient platelets, the extent of clot lysis was inversely proportional to platelet concentration, although more extensive lysis consistently was observed in the presence of PAI-1 -deficient platelets (Fig 3) . Hence, PAI-1 -deficient platelets inhibit clot lysis less than normal platelets. However, platelets lacking PAI-1 retain the capacity to inhibit fibrinolysis, and do so in a concentration-dependent manner. Of note, clot retraction was observed in this experimental system, and the extent of clot retraction (estimated by visual inspection) appeared proportional to platelet concentration.
Eflect ofplatelets on mutant t-PA-and streptokinase-mediated clot lysis. To further assess the role of platelet PAI-1 in regulating clot lysis, studies similar to those described above were performed, except that PAI-I-insensitive plasminogen activators (ie, t -P A~,~2 9 6 ,~~~2 9 8 ,~r g 2 9 9 -~, " or strep tokinase) were substituted for wild-type t-PA. In these experiments, the effects of platelets from the PAI-I -deficient individual were compared with those of her father's platelets. Platelet-rich clots were formed in the presence of mutant t-PA (1.5 U/mL) or streptokinase (8 mU/mL) and the rates of clot lysis were determined. In contrast to experiments with wild-type t-PA, clots containing PAI-l-deficient platelets (obtained from the proband) and those containing platelets with normal PAI-I content (obtained from the proband's father) lysed at similar rates when t-PA~ys-296,~rg-298,~rg299-~1~ (Fig 4A) or streptokinase ( Fig 4B) were used to initiate plasmin formation.
Comparison of wild-type and mutant t-PA in the lysis of platelet-rich clots. If platelet PAL1 contributes to plateletmediated clot lysis resistance, then a PAI-1 -insensitive t-PA should lyse platelet-rich clots more efficiently than wild-type t-PA. To test this hypothesis, either wild-type or mutant t-PA was used to lyse clots formed in the presence or absence of normal platelets. In preparation for these experiments, standard curves of t-PA concentration (both for wild-type and mutant enzymes) versus the percentage of clot lysis at l hour were constructed (data not shown) to allow selection of enzyme concentrations that resulted in essentially equal amounts of clot lysis in the absence of platelets (ie, 0.6 U/ mL wild-type t-PA and 2.0 ng/mL PAI-l-resistant t-PA). As shown in Fig 5 , using these concentrations of t-PA, similar rates of clot lysis were observed in the absence of platelets. However, in the presence of platelets (2.5 X 108/mL), the same concentrations of wild-type or mutant t-PA resulted in significantly different rates of clot lysis. Whereas normal platelets markedly inhibited the fibrinolytic capacity of wild-type t-PA, the fibrinolytic activity of PAI-l-resistant t-PA was minimally inhibited under these same conditions.
DISCUSSION
Several results from these in vitro experiments suggest that PAI-I is an important determinant of the antifibrinolytic effect of platelets. First, PAI-l -deficient platelets inhibited t-PA-mediated clot lysis to a substantially lesser extent than normal platelets. Second, the relative inhibition of fi- 
U/mL) and platelets (2.5 X 1 08/mL) and the percentage of clot lysis was determined at the indicated time points. (A) Homozygous PAl-l-deficient platelets (no detectable platelet PAI-1); (A) platelets from the proband's father (normal levels of platelet PAL1 ). (B) Streptokinase-mediated clot lysis. Experimental conditions were the same as for (A), except that streptokinase (8 mU/mL) was substituted for mutant t-PA. Labels are as in (A).
brinolysis by platelets with normal PAI-l content (compared with PAI-l-deficient platelets) was not observed when plasmin formation was initiated by PAI-l -insensitive plasminogen activators (ie, the PAI-1 -resistant t-PA mutant or streptokinase). And finally, PAI-1 -resistant t-PA was significantly more effective than wild-type t-PA in lysing clots containing normal platelets. However, these experiments also suggest that platelets inhibit fibrinolysis by a mechanism(s) that does not involve PAI-l. Although reduced compared with normal platelets, platelets lacking PAI-1 retained the capacity to inhibit fibrinolysis. These findings are consistent with a contribution of platelet-mediated clot retraction to lysis resistance, as suggested by Kunitada et al.I3 Indeed, visible clot retraction was observed during our experiments and appeared to be proportional to platelet concentration for both normal and PAI-1-deficient platelets.
The results of our studies are also consistent with the report of Levi et in which an anti-PAI-1 monoclonal antibody markedly accelerated the capacity of t-PA to lyse platelet-rich clots in vitro. These investigators also showed that this antibody, which inhibits the interaction of PAI-l with t-PA, enhances spontaneous clot lysis and inhibits thrombus extension in vivo. Braaten et a12* also showed that an anti-PAI-1 monoclonal antibody accelerates clot lysis in vitro. In addition, this group used immuno-electron microscopy to demonstrate that PAI-1 in platelet-rich thrombi is localized on fibrin, as opposed to the platelet surface, and that PAI-1 is particularly abundant on fibrin fibers that are closely associated with the platelet surface. These investigators hypothesize that the binding of PAI-1 to platelet-associated fibrin renders it more resistant to lysis, because fibrinbound PAL1 retains the capacity to inhibit t-PA.29,30 In contrast, in studies using pharmacologic concentrations of t-PA, Kunitada et all3 concluded that PAI-1 is not a determinant of platelet-mediated clot lysis inhibition. These investigators observed that a PAI-1 -resistant t-PA mutant at a concentration of 800 U/mL did not lyse platelet-rich clots faster than wild-type enzyme. In addition, no differences were observed in the t-PA activity of supernatants of clots prepared from platelet-poor versus platelet-rich plasma. The enhanced efficiency of a PAI-1-resistant t-PA (compared with wild-type enzyme) in our experimental system, but lack thereof in the experiments of Kunitada et a1,I3 is most likely explained by the substantial differences in t-PA concentrations used in the two studies (approximately 1,000-fold). Platelets contain approximately 4,000 molecules of PAL1 per cell.19 Therefore, in clot lysis experiments using a platelet concentration of 3 X 108/mL and a t-PA (specific activity, 580,000 U/mg) concentration of 800 U/ mL (ie, the conditions of Kunitada et all3), the molar ratio of t-PA:PAI-1 is 10: 1. In addition, because as much as 95% of platelet PAI-l is reported to exist in a latent, or inactive, the ratio of t-PA to functional inhibitor may have exceeded 100-fold in these experiments. Under these conditions, it is probably not possible to observe a PAI-l effect and, hence, to discriminate between the lytic efficiencies of wild-type and PAI-l -resistant enzymes. Taken together, these studies suggest that clot-associated PAL1 may inhibit endogenously mediated fibrinolysis, in which local t-PA concentrations are probably in the nanogram per milliter range,31 but not pharmacologically mediated fibrinolysis, in which plasma t-PA concentrations can exceed 1 pg/mLS3* For personal use only. on October 22, 2017. by guest www.bloodjournal.org From However, the concentration of platelets typically used in in vitro clot lysis assays ( lo8 to 109/mL5*6) is probably considerably less than the concentration of platelets within a hemostatic plug or platelet-rich thrombus. For example, in our experimental system, platelets constituted less than 1% of the total volume of the clot lysis mixture. However, microscopic evaluation of coronary thrombi retrieved from patients with acute myocardial infarction or sudden cardiac death shows that they consist, to a considerable extent, of essentially solid masses of platelets with interspersed islands of fibrin.' Hence, the concentration of PAI-1 in platelet-rich clots in vivo may be considerably higher than is present in in vitro assays. Consistent with this hypothesis, Potter van Loon et aP3 showed that the average amount of PAI-1 antigen in human arterial thrombi, which are frequently platelet-rich, is l50 times that detected in an equivalent volume of platelet-poor plasma. Similarly, the mean concentration of PAI-1 in experimentally induced porcine platelet-rich thrombi (36 pg/mL) exceeds that detected in plasma by greater than two orders of magnitude.34 Whether active PAI-I accumulates in human platelet-rich thrombi in sufficient concentrations to inhibit pharmacologically-induced fibrinolysis is unknown. However, platelets contain vitronectin, which stabilizes PAI-1 in the active conformation,35*36 and phospholipid vesicles can convert latent PAIl to the active form,37 suggesting that reactivation of latent PAI-1 may occur on cell surfaces in vivo.
In summary, our experiments with PAI-l-deficient platelets and plasminogen activators with differential sensitivity to inhibition by PAI-l suggest that PAI-I is an important determinant of platelet-dependent clot lysis inhibition in vitro. Our studies also suggest that platelets inhibit fibrinolysis in a PAI-l-independent manner, consistent with prior observations that platelet-mediated clot retraction inhibits fibrin01ysis.l~ Although these results suggest that platelet PAI-1 may play an important role in the regulation of fibrinolysis within the microenvironment of the platelet-rich clot, additional studies are necessary to adequately test this hypothesis. For example, animal studies comparing the lysis of platelet-rich thrombi in response to wild-type versus PAL 1-resistant t-PAs should help to define the role of PAL1 in platelet-mediated clot lysis inhibition in vivo. In addition to defining mechanisms underlying the inhibitory effect of platelets on fibrinolysis, such studies may also suggest alternative strategies for enhancing thrombolytic therapy in patients with acute thrombotic disease. 
